Neurology

Ofatumumab (Kesimpta) is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis.

Brexpiprazole is indicated as an adjunctive therapy to antidepressants in adults with major depressive disorder and as a treatment in adults with schizophrenia.

After 4 years of treatment with ofatumumab, 78.8% of patients with relapsing forms of multiple sclerosis who continuously received ofatumumab achieved NEDA-3 compared to 51.8% of those who switched from teriflunomide to ofatumumab.

Jazz Pharmaceuticals announced top-line results from the phase 3 RELEASE MSS1 trial, evaluating nabiximols oromucosal spray in individuals with multiple sclerosis.

Surprising turn of events is a strong message to the pharmaceutical industry about the acceptable developmental pathway for this drug class.

New data show that after 4 years of treatment, 78.8% of patients who continuously received ofatumumab achieved no evidence of disease activity-3 (NEDA-3) compared to 51.8% of those who switched from teriflunomide to ofatumumab.

Cenobamate is a once daily anti-epileptic medication with a recommended maintenance dose of 200 mg once daily that can be prescribed as monotherapy or adjunctive therapy.

Patients recorded their symptoms and use of acute medications in a headache diary.

Levetiracetam is an anticonvulsant used to treat epileptic seizures.

Natalizumab (Tysarbi) is an integrin receptor antagonist indicated for treatment of: multiple sclerosis and Crohn disease.

The symptoms of serotonin syndrome often include autonomic dysfunction, neuromuscular excitation, and altered mental status.

Specialty pharmacy is deeply engaged in providing treatment for conditions that are at high risk for mental health challenges.

Naxitamab-gqgk (Danyelza) is for the treatment of pediatric and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.

Studies have estimated that 16% of people with dementia experience depression, but this may be as high as 40%, demonstrating a great need for effective treatments.

Serotonin syndrome generally occurs within 6 hours of a change in dose or addition of medication.

Researchers also noted the importance of patient-reported outcomes due to the fluctuating and unpredictable nature of generalized myasthenia gravis and the subjectivity of symptoms.

Ravulizumab-cwvz (Ultomiris) is the first and only long-acting C5 complement inhibitor for the treatment of generalized myasthenia gravis to gain FDA approval.

Fremanezumab is the second FDA-approved preventive migraine treatment that blocks the activity of calcitonin gene-related peptide.

Conditions such as high blood pressure, diabetes, and obesity may have a significant impact on the likelihood of developing cognitive decline, dementia, and Alzheimer disease.

New analysis demonstrates that physical activity improves cognitive health, thus staving off dementia.

Fosdenopterin (Nulibry) is indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency Type A.

Haloperidol (Haldol) is indicated for use in the treatment of schizophrenia and to control the symptoms of Tourette's disorder, as well as severe behavioral problems or hyperactivity in children.

Eptinezumab is a calcitonin gene-related peptide antagonist FDA-approved for the preventive treatment of migraine.

Dhivy is a levodopa/carbidopa combination formulation approved by the FDA in November 2021 for the treatment of Parkinson disease or manifestations due to viral or environmental exposures.

Ponesimod (Ponvory) is indicated for the treatment of relapsing forms of multiple sclerosis.